Upcoming events

Upcoming events

myNEO Therapeutics will attend job fairs and participate in the following events: Biotech Showcase JPM Healthcare conference 2026 – San Francisco, USA – January 12-January 14, 2026 VIB Flanders-UK Immunology & Immunotherapy Partnering Forum – Ghent – February...

OUR LATEST POST

✨ Wrapping up our second thematic week!

Last week, our team paused the day-to-day work for our annual deep-dive into new technologies and scientific insights to help shape our roadmap for the coming year. It encourages us to stay curious, to push ourselves and our boundaries, and to keep innovating.This...

ALL POSTS

All

News

Press release

Article

Dec 9 2025

✨ Wrapping up our second thematic week!

Last week, our team paused the day-to-day work for our annual deep-dive into new technologies and scientific insights to help shape our roadmap for th...

Sep 23 2025

New publication: neoIM, a predictive model for neoantigen immunogenicity

neoIM is the first-in-class immunogenicity predictor with high accuracy in identifying which neoantigens are capable of eliciting a T-cell response. U...

Jun 12 2025

European Patent Office further protects myNEO’s IP position and computational platform!

🧬 neoMS and neoIM – myNEO’s proprietary algorithms for presentation and immunogenicity prediction – are the core of our ImmunoEngine pipel...

Apr 14 2025

CureVac Initiates Clinical Trial in Squamous Non-Small Cell Lung Cancer Based on Targets from myNEO Collaboration

We’re proud to share the LinkedIn post from our CEO, Cedric Bogaert, following CureVac’s announcement of U.S. FDA clearance to initiate a Phase 1 clin...

Feb 19 2025

Upcoming events

myNEO Therapeutics will attend job fairs and participate in the following events:

Feb 19 2025

The launch of neoHUB

neoHUB is our new 𝐭𝐮𝐦𝐨𝐫 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦, seamlessly integrating the 𝐈𝐦𝐦𝐮𝐧𝐨𝐄𝐧𝐠𝐢𝐧𝐞 with an 𝐢𝐧𝐭𝐞𝐫𝐚𝐜𝐭𝐢𝐯𝐞, 𝐮𝐬𝐞𝐫-𝐟𝐫𝐢𝐞𝐧𝐝𝐥𝐲 𝐯𝐢𝐬𝐮𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐢𝐧𝐭𝐞𝐫𝐟𝐚𝐜𝐞. Design...

Dec 9 2025

✨ Wrapping up our second thematic week!

Last week, our team paused the day-to-day work for our annual deep-dive into new technologies and scientific insights to help shape our roadmap for th...

Sep 23 2025

New publication: neoIM, a predictive model for neoantigen immunogenicity

neoIM is the first-in-class immunogenicity predictor with high accuracy in identifying which neoantigens are capable of eliciting a T-cell response. U...

Jun 12 2025

European Patent Office further protects myNEO’s IP position and computational platform!

🧬 neoMS and neoIM – myNEO’s proprietary algorithms for presentation and immunogenicity prediction – are the core of our ImmunoEngine pipel...

Apr 14 2025

CureVac Initiates Clinical Trial in Squamous Non-Small Cell Lung Cancer Based on Targets from myNEO Collaboration

We’re proud to share the LinkedIn post from our CEO, Cedric Bogaert, following CureVac’s announcement of U.S. FDA clearance to initiate a Phase 1 clin...

Feb 19 2025

Upcoming events

myNEO Therapeutics will attend job fairs and participate in the following events:

Feb 19 2025

The launch of neoHUB

neoHUB is our new 𝐭𝐮𝐦𝐨𝐫 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦, seamlessly integrating the 𝐈𝐦𝐦𝐮𝐧𝐨𝐄𝐧𝐠𝐢𝐧𝐞 with an 𝐢𝐧𝐭𝐞𝐫𝐚𝐜𝐭𝐢𝐯𝐞, 𝐮𝐬𝐞𝐫-𝐟𝐫𝐢𝐞𝐧𝐝𝐥𝐲 𝐯𝐢𝐬𝐮𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐢𝐧𝐭𝐞𝐫𝐟𝐚𝐜𝐞. Design...

Nov 22 2023

CureVac exercises options in strategic collaboration with myNEO Therapeutics.

GHENT, Belgium and Tübingen, Germany/Boston, USA – November 22, 2023 – myNEO N.V. (myNEO Therapeutics) and CureVac N.V. (Nasdaq CVAC) announced today ...

Oct 25 2023

myNEO evolves into myNEO Therapeutics

myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics. myNEO, a biotech company...

Feb 13 2023

Odimma partners with myNEO Therapeutics for the clinical development of its personalized DNA-based cancer immunotherapy

Odimma Therapeutics and myNEO Therapeutics will partner to identify personalized targets for clinical development of DNA-based cancer vaccine therapy....

May 25 2022

CureVac Partners with myNEO Therapeutics to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

CureVac (Nasdaq: CVAC) and myNEO Therapeutics will partner to identify novel targets for mRNA-based cancer vaccine development. We’re convinced that c...

Apr 7 2021

OncoDNA and myNEO Therapeutics Join Forces to Unlock the Power of Personalized Vaccines

Fighting Cancer with Personalized Vaccines: ONCODNA and myNEO Therapeutics collaboration OncoDNA, a company specializing in precision medicine, and my...

May 30 2024

SOB Case Study

Following antigen discovery and validation, mRNA construct design can be challenging. Read this case study to learn more about how to design multi-epi...

Nov 16 2023

myNEO Therapeutic’s CEO Cedric Bogaert receives Medical Genetics award at the Vatican!

myNEO Therapeutics has been quite active in recent months, taking part in various conference presentations and participating in panel discussions abou...

Oct 17 2023

Hookipa-HPV Case Study

Are AI-driven insights the future of precision medicine, reshaping clinical data analysis as we know it? The inherent complexity of cancer a...

Aug 1 2023

Bloovi interview

At myNEO Therapeutics we are devoted to finding new and better targets for immunotherapy. With our validated antigen discovery technology, our amazing...

Nov 23 2022

Review publication in Cancer Cell

myNEO Therapeutics is extremely excited to announce the publication in the Cancer Cell journal, written by myNEO Therapeutics colleagues Lien, Steve, ...

Nov 14 2022

myNEO Therapeutics has won the 2022 Most Disruptive Innovator award

myNEO Therapeutics has won Deloitte’s 2022 Most Disruptive Innovator award. This award, which is part of the Rising Star category of the Deloitt...

Innovating immunotherapies,
transforming tomorrow

Subscribe to our newsletter

Get the latest news & updates about myNEO Therapeutics

Home

About us

Products

Technology

Partners

Services

Contact

Quick links

Publications

Latest news

Privacy statement

Terms of use

Careers

Cookie statement

We use cookies to enhance your browsing experience and provide analytics. By continuing to use this website, you agree to our use of cookies. For more information, please read our privacy statement.

myNEO BV

Ottergemsesteenweg-Zuid 808 B511, 9000 Ghent, East-Flanders
Belgium (BE0715710837)

Assembled with care by
Design Studio Wim Mees